Dr Ying Kai Chan discusses his latest research into how the delivery of AAV vectors for gene therapies can be made safer and more effective.
List view / Grid view
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.